Year 2015 / Volume 107 / Number 9
Editorial
INTENSIFICATION OF MAINTENANCE THERAPY WITH INFLIXIMAB IN ULCERATIVE COLITIS

525-526

DOI: 10.17235/reed.2015.3907/2015

Francesc Casellas Jordá,

Abstract
In the past few years the pharmacopeia used for the treatment of ulcerative colitis has become notably more extensive and diverse, the introduction of biologics being the most significant novelty. Biologic drugs are produced from a biologic source
Share Button
New comment
Comments
No comments for this article
References
1. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 2012 18 January 2013. Disponible en:, http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500020062.
2. Dignass A, Lindsay JO, Sturm ÇA, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J Crohn’s Colitis 2012;6:991-1030.
3. Cabriada JL, Vera I, Domènech E, et al. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2013;36:127-46.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
5. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780–7.
6. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients withmoderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-9.
7. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49–54.
8. Arijs I, Li K, Toedter G, Quintens R, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612–9.
9. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy Gut. 2010;59:1363-8.
10. Filippi J, Laharie D, Michiels C, et al. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.J Crohns Colitis 2015;9:252-8.
11. Roblin X, Marotte H, Leclerc M, et al. Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease.J Crohns Colitis. 2015 Apr 19. pii: jjv061.
12. Huang VW, Prosser C, Kroeker KI, et al. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflamm Bowel Dis 2015;21:1359-67.
13. Chaparro M, Martínez-Montiel P, Van Domselaar M, et al. Intens.ification of infliximab therapy in Crohn's disease: efficacy and safety. J Crohns Colitis 2012;6:62-7.
14. Taxonera C, Olivares D, Mendoza JL, et al. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. W J Gastroenterol 2014;20:9170-7.
15. Taxonera C, Barreiro-de Acosta M, Calvo M, et al. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci. 2015 Jun 5.
16. Fernández-Salazar L, Barrio J, Muñoz F, et al. Frecuencia, factores predictores y consecuencias de la intensificación del tratamiento de mantenimiento con infliximab en la colitis ulcerosa. Rev Esp Enfs Dig.xxxxxxxxx
Related articles

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Citation tools
Casellas Jordá F. INTENSIFICATION OF MAINTENANCE THERAPY WITH INFLIXIMAB IN ULCERATIVE COLITIS. 3907/2015


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 45 visits.
This article has been downloaded 45 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 27/06/2015

Accepted: 29/06/2015

Published: 29/08/2015

Article editing time: 63 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology